Navigation Links
Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
Date:10/12/2009

r over thirty years in total, serving in roles such as vice president of human resources, vice president of pharmaceutical manufacturing, executive director of product operations and director of manufacturing strategy development. As the company's top executive for both manufacturing and human resources, Mr. Granadillo was responsible for the overall management of an extensive network of pharmaceutical manufacturing facilities and for policies affecting the company's global workforce of more than 43,000 employees. Mr. Granadillo received a B.S. in industrial engineering from Purdue University. He currently serves on the Board of Directors of Haemonetics Corporation, Nile Therapeutics and Tigris Pharmaceuticals.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

SOURCE Dendreon Corporation


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation ... release its second quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, August ... quarter and other business developments. Interested parties ...
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)...  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... of our Medicare resources and continue highlighting the success of the prescription drug benefit, ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
(Date:8/2/2015)... , ... August 03, 2015 , ... ... will be attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) ... , “We are pleased for the opportunity the AHDI conference provides us to ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... 2015 , ... For many “would be” entrepreneurs, starting a new business can prove to ... to start a business.” Neither needs be a major obstacle. , The U.S. has ... a business and be successful. The risks of starting a business can be high but ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... muscles and connective tissues of a woman’s pelvic organs (uterus, bladder, and ... straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the ...
(Date:8/2/2015)... ... 02, 2015 , ... Molecular biologists in New South Wales say a protein ... has just posted an article on the new research. Click here to read ... Ki67 expression in tissue samples from 42 patients with peritoneal mesothelioma and found a ...
Breaking Medicine News(10 mins):Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2
... Pyratine-6(TM) and Pyratine XR(TM)NAPA, Calif., March 31 Senetek ... engaged in the development of technologies that target the ... quarter and year ended December 31, 2008. Revenue for ... with $26,471,000 reported in 2007. Revenues for the ...
... 31 The following is a statement by Lois ... Senate Majority Leader Smith and Assembly Speaker Silver for ... benefit under one of New York,s most beneficial programs ... program was in danger of losing more than $50 ...
... CITY, Mo., March 31 DST Systems, Inc. (NYSE: ... 50% of Argus Health Systems, Inc. ("Argus"). Argus is now ... in this press release may include forward-looking statements respecting DST ... DST,s views as of today, and actual actions or results ...
... DIEGO, March 31 - Orexigen(R) Therapeutics, Inc. (Nasdaq: ... on the treatment of obesity, today announced that ... as President and Chief Executive Officer of the ... M.D., Executive Chairman and Interim President and CEO. ...
... JACKSONVILLE, Fla., March 31 MSC ... products and services to post-discharge and post-injury workers, ... acquired Optimal Translation & Transportation, a national company ... acquisition further fortifies MSC,s position in the market, ...
... 31, 2009 -- Scientists who first established a link ... live in the intestine now are investigating whether the ... Researchers at Washington University School of Medicine in St. ... whether severely malnourished infants living in Malawi and Bangladesh ...
Cached Medicine News:Health News:Senetek PLC Reports 2008 Financial Results 2Health News:Senetek PLC Reports 2008 Financial Results 3Health News:State Budget Preserves State Pharmacy Program for Seniors (EPIC) 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:MSC Acquires Optimal Translation & Transportation 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 3Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: